The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/akt signal pathways

Molecular Pharmacology

Volumn 78, Issue 1, 2010, Pages 142-150

  Kim, Chun Ki ^a   Choi, Yoon Kyung ^a   Lee, Hansoo ^a   Ha, Kwon Soo ^a   Won, Moo Ho ^b   Kwon, Young Guen ^c   Kim, Young Myeong ^a  

^a Kangwon National University   (South Korea)

^b Hallym University   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; LB 42708; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BASE SEQUENCE; CELL LINE; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PYRROLES; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953770159     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.063586     Document Type: Article

References (38)

1. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074.
2. Agrawal AG and Somani RR (2009) Farnesyltransferase inhibitor as anticancer agent. Mini Rev Med Chem 9:638-652.
3. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M, and Lam EW (2000) Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 275:21960-21968.
4. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, and Perret GY (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94:1823-1832.
5. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, and Wang Y (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174.
6. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803.
7. Foijer F and te Riele H (2006) Check, double check: the G2 barrier to cancer. Cell Cycle 5:831-836.
8. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235:442-447.
9. Greenberg JI and Cheresh DA (2009) VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 9:1347-1356.
10. Gu WZ, Tahir SK, Wang YC, Zhang HC, Cherian SP, O'Connor S, Leal JA, Rosenberg SH, and Ng SC (1999) Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer 35:1394-1401.
11. Guo D, Jia Q, Song HY, Warren RS, and Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270:6729-6733.
12. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, and Lee HY (2005) Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272-1286.
13. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, and Sukhatme VP (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277:16464-16469.
14. Head J and Johnston SR (2004) New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res 6:262-268.
15. Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, and Delattre JY (2008) Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 13:978-992.
16. Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, and Savatier P (2002) Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 21:5515-5528.
17. Kim HS, Kim JW, Gang J, Wen J, Koh SS, Koh JS, Chung HH, and Song SY (2006) The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells. Toxicol Appl Pharmacol 215:317-329.
18. Lee H, Lee J, Lee S, Shin Y, Jung W, Kim JH, Park K, Kim K, Cho HS, Ro S, et al. (2001) A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase). Bioorg Med Chem Lett 11:3069-3072.
19. Lee SJ, Namkoong S, Kim YM, Kim CK, Lee H, Ha KS, Chung HT, Kwon YG, and Kim YM (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291:H2836-H2846.
20. Li N, Wang C, Wu Y, Liu X, and Cao X (2009) Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation. J Biol Chem 284:3021-3027.
21. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, et al. (1998) Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58:4947-4956.
22. Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, and Grubbs CJ (2006) Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Mol Cancer Ther 5:1073-1078.
23. Min JK, Han KY, Kim EC, Kim YM, Lee SW, Kim OH, Kim KW, Gho YS, and Kwon YG (2004) Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 64:644-651.
24. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, and Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864-29872.
25. Na HJ, Lee SJ, Kang YC, Cho YL, Nam WD, Kim PK, Ha KS, Chung HT, Lee H, Kwon YG, et al. (2004) Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. J Immunol 173:1276-1283.
26. Namkoong S, Chung BH, Ha KS, Lee H, Kwon YG, and Kim YM (2008) Microscopic technique for the detection of nitric oxide-dependent angiogenesis in an animal model. Methods Enzymol 441:393-402.
27. Namkoong S, Lee SJ, Kim CK, Kim YM, Chung HT, Lee H, Han JA, Ha KS, Kwon YG, and Kim YM (2005) Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 37:588-600.
28. Pruitt K and Der CJ (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171:1-10.
29. Rak J, Yu JL, Klement G, and Kerbel RS (2000) Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 5:24-33.
30. Ravoet C, Mineur P, Robin V, Debusscher L, Bosly A, André M, El Housni H, Soree A, Bron D, and Martiat P (2008) Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 87:881-885.
31. Rodenhuis S (1992) Ras and human tumors. Semin Cancer Biol 3:241-247.
32. Schubbert S, Shannon K, and Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308.
33. Scott AN, Hetheridge C, Reynolds AR, Nayak V, Hodivala-Dilke K, and Mellor H (2008) Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. Angiogenesis 11:337-346.
34. Serban D, Leng J, and Cheresh D (2008) H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res 102:1350-1358.
35. Shankar E, Sivaprasad U, and Basu A (2008) Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53. Oncogene 27:3957-3966.
36. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, and Fontana JA (1994) Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9:3407-3415.
37. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20:187-190.
38. Zachary I (2003) VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31:1171-1177.